foscarnet has been researched along with Encephalitis in 15 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Encephalitis: Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 7.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 7.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 7.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 3.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 3.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 3.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| "How to treat cytomegalovirus infections in patients infected with the human immunodeficiency virus constitutes one of the best examples of the quandaries engendered by these advances, and the topic is reviewed in this first AIDS Commentary update." | 2.38 | Cytomegalovirus infection in patients with AIDS. ( Drew, WL, 1992) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| "Encephalitis is the inflammation of the brain parenchyma accompanied by mental or behavioral neurological dysfunction, sensory or motor deficits, speech or movement disorders, and seizure." | 1.91 | [Severe Encephalitis with Human Herpes Virus-7 (HHV-7) Associated Transient Splenial Lesion in an Immunocompetent Child: A Case Report]. ( Akça, M; Çobanoğulları Direk, M; Ersoy, Ö; Kuyucu, N; Özgökçe Özmen, B, 2023) |
| "Effective diagnosis and treatment of cytomegalovirus infection of the nervous system in AIDS patients has been limited by a lack of sensitive diagnostic measures." | 1.29 | Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. ( Cohen, BA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akça, M | 1 |
| Özgökçe Özmen, B | 1 |
| Ersoy, Ö | 1 |
| Çobanoğulları Direk, M | 1 |
| Kuyucu, N | 1 |
| Ogata, M | 1 |
| Phan, TL | 1 |
| Fukuda, T | 1 |
| Ishiyama, K | 1 |
| Katagiri, T | 1 |
| Hoshino, T | 1 |
| Yoshida, T | 1 |
| Yamaguchi, M | 1 |
| Nakao, S | 1 |
| Capobianchi, A | 1 |
| Iori, AP | 1 |
| Mauro, FR | 1 |
| Torelli, GF | 1 |
| Micozzi, A | 1 |
| Girmenia, C | 1 |
| Foà, R | 1 |
| Gentile, G | 1 |
| Nash, PJ | 1 |
| Avery, RK | 1 |
| Tang, WH | 1 |
| Starling, RC | 1 |
| Taege, AJ | 1 |
| Yamani, MH | 1 |
| Berman, SM | 1 |
| Kim, RC | 1 |
| Hengge, UR | 1 |
| Brockmeyer, NH | 1 |
| Malessa, R | 1 |
| Ravens, U | 1 |
| Goos, M | 1 |
| Cohen, BA | 1 |
| Drew, WL | 1 |
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Pinching, AJ | 1 |
| Reefschläger, J | 2 |
| Wutzler, P | 2 |
| Thiel, KD | 2 |
| Herrmann, G | 2 |
| Dolin, R | 1 |
| Ayisi, NK | 1 |
| Gupta, SV | 1 |
| Babiuk, LA | 1 |
2 reviews available for foscarnet and Encephalitis
| Article | Year |
|---|---|
Cytomegalovirus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Chorioretinitis; Cytomegalovirus Infections; Encephalitis; Fosca | 1992 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
2 trials available for foscarnet and Encephalitis
| Article | Year |
|---|---|
Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT.
Topics: Adolescent; Adult; Chemoprevention; DNA, Viral; Encephalitis; Female; Foscarnet; Hematopoietic Stem | 2011 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
11 other studies available for foscarnet and Encephalitis
| Article | Year |
|---|---|
[Severe Encephalitis with Human Herpes Virus-7 (HHV-7) Associated Transient Splenial Lesion in an Immunocompetent Child: A Case Report].
Topics: Acyclovir; Antiviral Agents; Child; Encephalitis; Female; Foscarnet; Herpesvirus 7, Human; Humans; I | 2023 |
Antiviral therapy for the treatment of HHV-6-associated syndromes after transplant.
Topics: Antiviral Agents; Control Groups; Cord Blood Stem Cell Transplantation; Encephalitis; Foscarnet; Gan | 2019 |
Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient.
Topics: Antibodies, Viral; Cidofovir; Cytosine; DNA, Viral; Encephalitis; Fatal Outcome; Foscarnet; Ganciclo | 2011 |
Encephalitis owing to human herpesvirus-6 after cardiac transplant.
Topics: Adult; Antiviral Agents; Cytomegalovirus; DNA, Viral; Encephalitis; Foscarnet; Heart Transplantation | 2004 |
The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Cerebral Ventricles; Confusion; Cytomegalovirus | 1994 |
Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Blood-Brain Barrier; Cytomegalovirus Infections; Encep | 1993 |
Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cerebrospi | 1996 |
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cells, Cultured; Encephalitis; Female; | 1987 |
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses.
Topics: Acyclovir; Animals; Antiviral Agents; Deoxyuridine; DNA, Viral; Drug Combinations; Drug Resistance, | 1985 |
Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
Topics: Acyclovir; Animals; Arabinofuranosyluracil; Bromodeoxyuridine; Cells, Cultured; Encephalitis; Female | 1986 |